[1]LINDAHL T,BARNES DE.Repair of endogenous DNA damage［J］.Cold Spring Harbor Symposia on Quantitative Biology,2000,65:127-133.
[2]PEARL LH,SCHIERZ AC,WARD SE,et al.Therapeutic opportunities within the DNA damage response［J］.Nature Reviews Cancer,2015,15(3):166-180.
[3]VIJG J,BUSUTTIL RA,BAHAR R,et al.Aging and genome maintenance［J］.Annals of the New York Academy of Sciences,2005,1055:35-47.
[4]SUN P,ZHAO YF.P53-related nonclassical cell death［J］.Chin J Oncology Biotherapeutics,2019,26(5):577-582.
[5]RIMAR KJ,TRAN PT,MATULEWICZ RS,et al.The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies［J］.Cancer,2017,123(11):1912-1924.
[6]BRADLEY MO,KOHN KW.X-ray induced DNA double strand break production and repair in mammalian cells as measured by neutral filter elution［J］.Nucleic Acids Research,1979,7(3):793-804.
[7]SABHARWAL SS,SCHUMACKER PT.Mitochondrial ROS in cancer:initiators,amplifiers or an Achilles' heel［J］.Nature Reviews Cancer,2014,14(11):709-721.
[8]CECCALDI R,RONDINELLI B,D'ANDREA AD.Repair pathway choices and consequences at the double-strand break［J］.Trends in Cell Biology,2016,26(1):52-64.
[9]CALDECOTT KW.DNA single-strand break repair［J］.Experimental Cell Research,2014,329(1):2-8.
[10]HANAHAN D,WEINBERG RA.Hallmarks of cancer:the next generation［J］.Cell,2011,144(5):646-674.
[11]FRIEDBERG EC.A brief history of the DNA repair field［J］.Cell Research,2008,18(1):3-7.
[12]PRITCHARD CC,MATEO J,WALSH MF,et al.Inherited DNA-repair gene mutations in men with metastatic prostate cancer［J］.N Engl J Med,2016,375(5):443-453.
[13]NA JC,NAGAYA N,RHA KH,et al.DNA damage response pathway alteration in locally advanced clear-cell renal-cell carcinoma is associated with a poor outcome［J］.Clinical Genitourinary Cancer,2019,17(4):299-305.
[14]GED Y,CHAIM JL,DINATALE RG,et al.DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy［J］.J Immunother Cancer,2020,8(1):e000230.
[15]TEO MY,BAMBURY RM,ZABOR EC,et al.DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma［J］.Clinical Cancer Research,2017,23(14):3610-3618.
[16]陈威佐,唐君霞,赵达,等.碳离子治疗恶性肿瘤研究进展［J］.中国肿瘤,2019,3(28):208-213.
CHEN WZ,TANG JX,ZHAO D,et al.Research progress of carbon ion therapy for malignant tumor［J］.Chin J Oncol,2019,3(28):208-213.
[17]LORD CJ,ASHWORTH A.PARP inhibitors:Synthetic lethality in the clinic［J］.Science (New York,NY),2017,355(6330):1152-1158.
[18]曹寒雨,楼江燕.DNA双链断裂修复通路和卵巢癌的关系［J］.现代肿瘤医学,2016,24(4):657-659.
CAO HY,LOU JY.The association between DNA double-strand break repair pathways and ovarian cancer［J］.Modern Oncology,2016,24(4):657-659.
[19]ASHWORTH A,LORD CJ.Synthetic lethal therapies for cancer:what's next after PARP inhibitors［J］.Nature Reviews Clinical Oncology,2018,15(9):564-576.
[20]OKAZAKI A,GAMEIRO PA,CHRISTODOULOU D,et al.Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers［J］.J Clin Invest,2017,127(5):1631-1645.
[21]JIAN W,XU HG,CHEN J,et al.Activity of CEP-9722,a poly (ADP-ribose) polymerase inhibitor,in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage［J］.Anti-cancer Drugs,2014,25(8):878-886.
[22]CLARKE N,WIECHNO PJ,ALEKSEEV B,et al.Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC):A randomized phase II trial［J］.J Clin Oncol,2018,36(15):2.
[23]CLEARY JM,AGUIRRE AJ,SHAPIRO GI,et al.Biomarker-guided development of DNA repair inhibitors［J］.Mol Cell,2020,78(6):1070-1085.
[24]REN W,XUE B,CHEN M,et al.Low expression of ATM indicates a poor prognosis in clear cell renal cell carcinoma［J］.Clinical Genitourinary Cancer,2019,17(3):e433-e439.
[25]HUANG AC,CHENG YD,HUANG LH,et al.Casticin induces DNA damage and impairs DNA repair in human bladder cancer TSGH-8301 cells［J］.Anticancer Research,2019,39(4):1839-1847.
[26]MARSHALL CH,SOKOLOVA AO,MCNATTY AL,et al.Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations［J］.European Urology,2019,76(4):452-458.
[27]NEEB A,HERRANZ N,ARCE-GALLEGO S,et al.Advanced prostate cancer with ATM loss: PARP and ATR inhibitors［J］.European Urology,2021,79(2):200-211.
[28]BROWN JS,O' CARRIGAN B,JACKSON SP,et al.Targeting DNA repair in cancer:beyond PARP inhibitors［J］.Cancer Discovery,2017,7(1):20-37.
[29]WILLERS H,DAHM-DAPHI J,POWELL SN.Repair of radiation damage to DNA［J］.British Journal of Cancer,2004,90(7):1297-1301.
[30]MORTENSEN DS,PERRIN-NINKOVIC SM,SHEVLIN G,et al.Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115［J］.Journal of Medicinal Chemistry,2015,58(14):5599-5608.
[31]MUNSTER PN,MAHIPAL A,NEMUNAITIS JJ,et al.Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers［J］.J Clin Oncol,2016,34(15):2.
[32]CHATTERJEE P,CHOUDHARY GS,ALSWILLAH T,et al.The TMPRSS2-ERG gene fusion blocks XRCC4-mediated nonhomologous end-joining repair and radiosensitizes prostate cancer cells to PARP inhibition［J］.Molecular Cancer Therapeutics,2015,14(8):1896-1906.
[33]ZHENG B,MAO JH,LI XQ,et al.Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation,HIF-2alpha expression and cell proliferation［J］.Scientific Reports,2016,6:29415.
[34]DYLGJERI E,MCNAIR C,GOODWIN JF,et al.Pleiotropic impact of DNA-PK in cancer and implications for therapeutic strategies［J］.Clinical Cancer Research,2019,25(18):5623-5637.
[35]MATTHEWS TP,JONES AM,COLLINS I.Structure-based design,discovery and development of checkpoint kinase inhibitors as potential anticancer therapies［J］.Expert Opinion on Drug Discovery,2013,8(6):621-640.
[36]ISONO M,HOFFMANN MJ,PINKERNEIL M,et al.Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine［J］.Journal of Experimental & Clinical Cancer Research:CR,2017,36(1):1.
[37]KARANIKA S,KARANTANOS T,LI L,et al.Targeting DNA damage response in prostate cancer by inhibiting androgen receptor-CDC6-ATR-Chk1 signaling［J］.Cell Reports,2017,18(8):1970-1981.
[38]AARTS M,SHARPE R,GARCIA-MURILLAS I,et al.Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1［J］.Cancer Discovery,2012,2(6):524-539.
[39]CHEN B,DUAN L,YIN G,et al.Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells-Cdc2 activity is up-regulated by targeting WEE1［J］.Clinics (Sao Paulo,Brazil),2013,68(6):825-833.